And as I, uh, touched on before, I, I'd love to learn again a bit more, uh, a lot more about BioRestorative's approach to developing therapies for conditions like, uh, degenerative disc disease and, uh, uh, cell-based, uh, therapy specifically.

So we're-- you know, our product is called BRTX-one hundred.

It's an autologous stem cell therapy.

It's designed to treat chronic lumbar disc disease.

Um, the therapy uses the patient's own bone marrow stem cells.

Uh, they're mesenchymal cells.

They're processed under a ver- specialized conditions and delivered via a minimally invasive injection directly into the nucleus of the damaged disc.

And what can we expect to hear and see from BioRestorative in the, the coming year and then, and in the next coming, uh, in the next couple of years in terms of important milestones, um, and such?